Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels. Our objective was to ascertain...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Kim, Yong-Un, Jukema, J. Wouter, Pordy, Robert, Roe, Matthew T., White, Harvey D., Bhatt, Deepak L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242174/
https://www.ncbi.nlm.nih.gov/pubmed/32223446
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242174/
https://www.ncbi.nlm.nih.gov/pubmed/32223446
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046524

Ejemplares similares